Hyderabad based Natco Pharma has been granted compulsory license for Sarofenib Tosylate (Brand name: Nexavar owned by Bayer Corporation). Nexavar is the first line treatment for liver and kidney cancer. The compulsory license, first of its kind, enables the company to sell the drug at a price not exceeding Rs 8880 for a pack of 120 tablets (one month’s therapy) against Rs 284,428 being the cost of Nexavar sold by bayer. The license is valid till the expiry of the patent -2021.
The order is however subject to certain condition such as maintaining account of sales, and payment of royalty at 6% of the net sales on a quarterly basis, etc. The order also makes it obligatory for NATCO to supply the drug free of cost at least 600 needy and deserving patients per year.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets. The company began its operations in 1984 in Andhra Pradesh.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1875.00 |
| Dr. Reddys Lab | 1283.90 |
| Cipla | 1336.45 |
| Zydus Lifesciences | 939.65 |
| Lupin | 2250.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: